Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:brand |
Alunbrig
|
| gptkbp:chemical_formula |
C22 H24 Cl N5 O2 S
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:ARIAD_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brigatinib
|
| gptkbp:mechanism_of_action |
ALK inhibitor
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
nausea diarrhea pneumonitis elevated liver enzymes |
| gptkbp:targets |
gptkb:anaplastic_lymphoma_kinase_(ALK)
epidermal growth factor receptor (EGFR) |
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:weight |
429.97 g/mol
|
| gptkbp:bfsParent |
gptkb:Retevmo
|
| gptkbp:bfsLayer |
5
|